CSIMarket
 


Surrozen Inc   (SRZN)
Other Ticker:  
 

Surrozen Inc 's Working Capital Ratio

SRZN's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 7.25 below Surrozen Inc average.

Within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Working Capital Ratio than Surrozen Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 308, from total ranking in the second quarter 2023 at 521.

Explain Working Capital Ratio
How much in Current Assets SRZN´s has?
What is the value of SRZN´s Current Liabilities?


SRZN Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -22.9 % -24.32 % -4.02 % -28.3 % -30.99 %
Y / Y Current Assets Change -41.54 % -39.27 % -29.94 % -22.71 % -27.44 %
Working Capital Ratio MRQ 7.25 8.93 8.61 8.35 9.56
SRZN's Total Ranking # 308 # 521 # 607 # 605 # 616
Seq. Current Liabilities Change 3.43 % -17.18 % -19.97 % 12.46 % 1.53 %
Seq. Current Assets Change -16.02 % -14.1 % -17.55 % -1.71 % -12.76 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 140
Overall Market # 308


Working Capital Ratio Statistics
High Average Low
11.79 7.68 0.59
(Mar 31 2022)   (Jun 30 2021)




Financial Statements
Surrozen Inc 's Current Liabilities $ 7 Millions Visit SRZN's Balance sheet
Surrozen Inc 's Current Assets $ 48 Millions Visit SRZN's Balance sheet
Source of SRZN's Sales Visit SRZN's Sales by Geography


Cumulative Surrozen Inc 's Working Capital Ratio

SRZN's Working Capital Ratio for the trailling 12 Months

SRZN Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -22.9 % -24.32 % -4.02 % -28.3 % -30.99 %
Y / Y Current Assets TTM Growth -41.54 % -39.27 % -29.94 % -22.71 % -27.44 %
Working Capital Ratio TTM 8.3 8.85 9.39 10.12 9.74
Total Ranking TTM # 3779 # 345 # 3759 # 3765 # 420
Seq. Current Liabilities TTM Growth 3.43 % -17.18 % -19.97 % 12.46 % 1.53 %
Seq. Current Assets TTM Growth -16.02 % -14.1 % -17.55 % -1.71 % -12.76 %


On the trailing twelve months basis In spite of the year on year decrease in SRZN's Current Liabilities to $6.67 millions, cumulative Working Capital Ratio to 8.3 below the SRZN average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 163 other companies have achieved higher Working Capital Ratio than Surrozen Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 345 to 3779.

Explain Working Capital Ratio
How much in Current Assets SRZN´s has?
What is the value of SRZN´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 164
Healthcare Sector # 995
Within the Market # 3779


trailing twelve months Working Capital Ratio Statistics
High Average Low
10.12 8.78 6.46
(Dec 31 2022)   (Sep 30 2021)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Graphite Bio Inc   19.05 $ 238.783  Millions$ 12.537  Millions
Tourmaline Bio Inc   18.64 $ 151.047  Millions$ 8.105  Millions
Avrobio Inc   18.47 $ 109.170  Millions$ 5.912  Millions
Compass Therapeutics Inc   18.26 $ 166.584  Millions$ 9.124  Millions
4d Molecular Therapeutics Inc   18.07 $ 328.243  Millions$ 18.163  Millions
Icosavax Inc   18.06 $ 235.307  Millions$ 13.030  Millions
Neumora Therapeutics Inc   18.05 $ 525.735  Millions$ 29.123  Millions
Fusion Pharmaceuticals Inc   17.97 $ 203.265  Millions$ 11.312  Millions
Hillevax Inc   17.58 $ 333.195  Millions$ 18.958  Millions
Relay Therapeutics Inc   16.39 $ 831.798  Millions$ 50.748  Millions
Denali Therapeutics Inc   16.06 $ 1,142.884  Millions$ 71.180  Millions
Crispr Therapeutics Ag  15.83 $ 1,760.586  Millions$ 111.234  Millions
Cabaletta Bio Inc   15.65 $ 166.178  Millions$ 10.616  Millions
Voyager Therapeutics Inc   15.03 $ 261.925  Millions$ 17.427  Millions
Iteos Therapeutics Inc   14.28 $ 619.128  Millions$ 43.349  Millions
Caribou Biosciences Inc   14.27 $ 350.693  Millions$ 24.572  Millions
Aura Biosciences Inc   14.13 $ 153.888  Millions$ 10.894  Millions
Vor Biopharma Inc   14.12 $ 164.438  Millions$ 11.645  Millions
Pharmacyte Biotech Inc   14.08 $ 73.748  Millions$ 5.240  Millions
Vigil Neuroscience Inc   13.79 $ 139.847  Millions$ 10.142  Millions
Molecular Partners Ag  13.35 $ 192.459  Millions$ 14.416  Millions
Anavex Life Sciences Corp   13.29 $ 154.386  Millions$ 11.617  Millions
Elevation Oncology inc   12.99 $ 98.797  Millions$ 7.607  Millions
Ambrx Biopharma Inc   12.80 $ 233.818  Millions$ 18.268  Millions
Replimune Group Inc   12.76 $ 508.175  Millions$ 39.832  Millions
Allogene Therapeutics inc   12.58 $ 473.454  Millions$ 37.636  Millions
Scholar Rock Holding Corp  11.70 $ 228.465  Millions$ 19.530  Millions
Kymera Therapeutics Inc   11.66 $ 375.694  Millions$ 32.219  Millions
Protara Therapeutics Inc   11.49 $ 77.813  Millions$ 6.775  Millions
Tarsus Pharmaceuticals Inc   11.15 $ 259.277  Millions$ 23.249  Millions

Date modified: 2023-12-22T09:50:26+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com